ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0546

Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice

Nehad Soloman1, Jawad Bilal2 and John Tesser3, 1Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, 2Arizona Arthritis & Rheumatology Associates, PC, Tucson, AZ, 3Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ

Meeting: ACR Convergence 2024

Keywords: Access to care, Ankylosing spondylitis (AS), Back pain, Measurement Instrument, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting 1.4% of the US adult population.  The leading clinical symptom of axSpA is chronic inflammatory back pain (IBP) with onset before age 45 years.  Diagnostic delay and under recognition of the disease results in poor long-term outcomes.  Moreover, current healthcare shortages impose higher demands on healthcare providers and limit their ability to adequately manually screen for underlying conditions such as axSpA.  To address these challenges, this study aimed to assess the impact of implementing an automated IBP screening tool into the electronic health record (EHR) on the identification of axSpA in both new and established patients in a community rheumatology practice.

Methods: A validated and accepted (IBP) screening tool was integrated into the EHR patient intake form through an innovative partnership between NextGen Healthcare, Ecosystem partners, and a large community rheumatology practice (12 clinics) in the Southwest US.  Customized alerts were automatically generated by the EHR and sent to the treating rheumatologist for review.  Additional customized EHR query sets were employed to identify patients who may have initially been missed. New patients were defined as those with a first or second visit that occurred during the study period of October 2021 to October 2023. Established patients were defined as those with a third or subsequent visit that occurred before January 1, 2023.

Results: Among 19,875 new patients screened, 1,457 (7.3%) had a positive IBP screening form. Of patients with a positive IBP result, 180 (12.4%) were subsequently diagnosed with axSpA. A separate analysis of 94,606 established patients identified 223 patients (0.24%) who had a positive IBP screening form, and of these, 61 (27.4%) had a subsequent diagnosis of axSpA. Ultimately, a total of 14.3% of all positive IBP screening forms resulted in a diagnosis of axSpA.

Conclusion: Implementation of an automated IBP screening tool into the EHR within community practices may help with the rapid identification of patients with axSpA, leading to earlier diagnosis. This can reduce existing gaps in care by identifying patients within an existing practice who have been missed, and potentially improve long-term outcomes as a result of earlier initiation of therapeutic intervention.


Disclosures: N. Soloman: AbbVie/Abbott, 6, Amgen, 6, AstraZeneca, 6, aurinia, 2, GlaxoSmithKlein(GSK), 6, Janssen, 6, Novartis, 2, UCB, 6; J. Bilal: None; J. Tesser: AbbVie/Abbott, 1, 2, 5, 6, Alpine, 5, Amgen, 1, 2, 5, 6, Anthrosi Therapeutics, 5, AstraZeneca, 1, 2, 5, 6, Aurinia, 1, 2, 5, 6, Bendcare, 5, 6, Biogen, 5, 6, Boehringer-Ingelheim, 1, 2, 5, 6, Bristol-Myers Squibb(BMS), 1, 2, 5, 6, Celgene, 5, Corevitas, 5, CSL Behring, 5, DRL, 5, Eli Lilly, 1, 2, 5, 6, Emerald, 5, Exagen, 5, Genentech, 5, 6, Gilead, 5, GlaxoSmithKlein(GSK), 1, 2, 5, 6, Global Health Living Foundation, 5, Horizon, 5, Janssen, 1, 2, 5, 6, Kolon TissueGene, 5, Merck/MSD, 5, Mitsubishi, 5, Novartis, 1, 2, 5, Organogenesis, 5, Pfizer, 1, 2, 5, 6, Roche, 5, Samumed/Biosplice, 1, 2, 5, Sanofi/Genzyme, 1, 2, 5, 6, Selecta, 5, Setpoint, 2, 5, Sun Pharma, 5, Takeda, 5, UCB, 1, 2, 5, Vindico, 6, Vorso, 5.

To cite this abstract in AMA style:

Soloman N, Bilal J, Tesser J. Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/hiding-in-plain-sight-the-impact-of-implementing-an-automated-inflammatory-back-pain-screening-tool-on-the-identification-of-axial-spondyloarthritis-in-a-community-rheumatology-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hiding-in-plain-sight-the-impact-of-implementing-an-automated-inflammatory-back-pain-screening-tool-on-the-identification-of-axial-spondyloarthritis-in-a-community-rheumatology-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology